caa a22 4500 605491615 CHVBK 20210128100511.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0786-7 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0786-7 Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan [Elektronische Daten] [Kazuo Tamura, Keisuke Aiba, Toshiaki Saeki, Yoichi Nakanishi, Toshiharu Kamura, Hideo Baba, Kazuhiro Yoshida, Nobuyuki Yamamoto, Yuko Kitagawa, Yoshihiko Maehara, Mototsugu Shimokawa, Koichi Hirata, Masaki Kitajima] Background: Many cancer patients suffer from the common side effect of chemotherapy-induced nausea and vomiting (CINV). Guidelines recommend a combination of two prophylactic antiemetics for moderately emetogenic chemotherapy (MEC) and three for highly emetogenic chemotherapy (HEC) and certain MEC regimens. Methods: This multicenter, prospective, observational study analyzed data for 1,910 patients in Japan scheduled for MEC or HEC. Use of antiemetic prophylaxis in relation to type of chemotherapy, incidences of and risk factors for nausea, vomiting, and acute versus delayed CINV, and estimated incidence of CINV by staff were analyzed using Fisher's exact test and multivariate logistic regression. The patients recorded the incidence of CINV and severity of nausea by visual analogue scales daily for 7days after receiving chemotherapy. Results: A total of 240 (20.1%) HEC and 476 MEC patients (66.6%) received 2 antiemetics, compared with 883 (73.9%) and 200 (28.0%), respectively, who received 3 antiemetics. Approximately 74% of HEC and 95% of MEC patients received antiemetic therapy in compliance with guidelines. Acute nausea and vomiting were well controlled, but high incidences of delayed nausea occurred in both HEC and MEC patients. Delayed vomiting (p<0.0001) was significantly less frequent in patients receiving three compared with 2 antiemetics. Female sex was a major risk factor for CINV. Medical staff tended to overestimate the incidence of CINV. Among HEC regimens, the incidence of CINV and the degree of nausea on day 1 of anthracycline-cyclophosphamide combination therapy were higher than with a cisplatin-based regimen. Conclusions: Adherence to antiemetic guidelines effectively controls vomiting but is less effective against delayed nausea in HEC and MEC patients. Identification of individual risk factors, such as female sex, will assist in the development of personalized treatments for CINV. More intensive antiemetic therapy or a different modality of prophylaxis should be considered for the control of acute CINV in an anthracycline-cyclophosphamide regimen. Japan Society of Clinical Oncology, 2015 Cancer chemotherapy nationallicence Antiemetics nationallicence Guidelines nationallicence Nausea nationallicence Vomiting nationallicence Tamura Kazuo Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, School of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-ku, 814-0180, Fukuoka, Fukuoko, Japan aut Aiba Keisuke Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, 105-8461, Tokyo, Japan aut Saeki Toshiaki Breast Oncology Service, Saitama Medical University International Medical Center, 1397-1, Yamane, 350-1298, Hidaka, Saitama, Japan aut Nakanishi Yoichi Research Institute for Diseases of the Chest, Kyushu University, 3-1-1, Maidashi, Higashi-ku, 812-8582, Fukuoka, Fukuoka, Japan aut Kamura Toshiharu Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67, Asahimachi, 830-0011, Kurume, Fukuoka, Japan aut Baba Hideo Department of Gastroenterological Surgery, Kumamoto University, 1-1-1, Honjomachi, Chuo-ku, 860-0811, Kumamoto, Kumamoto, Japan aut Yoshida Kazuhiro Department of Surgical Oncology, Gifu University, 1-1 Yanagito, 501-1194, Gifu, Gifu, Japan aut Yamamoto Nobuyuki Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Nagaizumicho, Sunto-gun, 411-0934, Shizuoka, Japan aut Kitagawa Yuko Department of Surgery, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, 160-0016, Tokyo, Japan aut Maehara Yoshihiko Department of Surgery and Science, Kyushu University, 3-1-1, Maidashi, Higashi-ku, 812-8582, Fukuoka, Fukuoka, Japan aut Shimokawa Mototsugu Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, 811-1395, Fukuoka, Fukuoka, Japan aut Hirata Koichi Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, S1 W17, Chuo-ku, 060-8556, Sapporo, Hokkaido, Japan aut Kitajima Masaki International University of Health and Welfare, 2600-1 Kitakanemaru, 324-8501, Ohtawara, Tochigi, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 855-865 1341-9625 20:5<855 2015 20 10147 https://doi.org/10.1007/s10147-015-0786-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0786-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tamura Kazuo Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, School of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-ku, 814-0180, Fukuoka, Fukuoko, Japan aut NATIONALLICENCE 700 1- Aiba Keisuke Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, 105-8461, Tokyo, Japan aut NATIONALLICENCE 700 1- Saeki Toshiaki Breast Oncology Service, Saitama Medical University International Medical Center, 1397-1, Yamane, 350-1298, Hidaka, Saitama, Japan aut NATIONALLICENCE 700 1- Nakanishi Yoichi Research Institute for Diseases of the Chest, Kyushu University, 3-1-1, Maidashi, Higashi-ku, 812-8582, Fukuoka, Fukuoka, Japan aut NATIONALLICENCE 700 1- Kamura Toshiharu Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67, Asahimachi, 830-0011, Kurume, Fukuoka, Japan aut NATIONALLICENCE 700 1- Baba Hideo Department of Gastroenterological Surgery, Kumamoto University, 1-1-1, Honjomachi, Chuo-ku, 860-0811, Kumamoto, Kumamoto, Japan aut NATIONALLICENCE 700 1- Yoshida Kazuhiro Department of Surgical Oncology, Gifu University, 1-1 Yanagito, 501-1194, Gifu, Gifu, Japan aut NATIONALLICENCE 700 1- Yamamoto Nobuyuki Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Nagaizumicho, Sunto-gun, 411-0934, Shizuoka, Japan aut NATIONALLICENCE 700 1- Kitagawa Yuko Department of Surgery, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, 160-0016, Tokyo, Japan aut NATIONALLICENCE 700 1- Maehara Yoshihiko Department of Surgery and Science, Kyushu University, 3-1-1, Maidashi, Higashi-ku, 812-8582, Fukuoka, Fukuoka, Japan aut NATIONALLICENCE 700 1- Shimokawa Mototsugu Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, 811-1395, Fukuoka, Fukuoka, Japan aut NATIONALLICENCE 700 1- Hirata Koichi Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, S1 W17, Chuo-ku, 060-8556, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Kitajima Masaki International University of Health and Welfare, 2600-1 Kitakanemaru, 324-8501, Ohtawara, Tochigi, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 855-865 1341-9625 20:5<855 2015 20 10147